RAPT Therapeutics, Inc. (RAPT) Free Cash Flow (2020 - 2024)
RAPT Therapeutics' Free Cash Flow history spans 5 years, with the latest figure at -$10.4 million for Q4 2024.
- For Q4 2024, Free Cash Flow rose 62.47% year-over-year to -$10.4 million; the TTM value through Dec 2024 reached -$83.4 million, up 15.03%, while the annual FY2024 figure was -$83.4 million, 15.03% up from the prior year.
- Free Cash Flow for Q4 2024 was -$10.4 million at RAPT Therapeutics, up from -$17.6 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$6.4 million in Q2 2020 and bottomed at -$29.0 million in Q2 2023.
- The 5-year median for Free Cash Flow is -$16.5 million (2022), against an average of -$17.8 million.
- The largest annual shift saw Free Cash Flow crashed 117.52% in 2021 before it surged 62.47% in 2024.
- A 5-year view of Free Cash Flow shows it stood at -$15.5 million in 2020, then tumbled by 35.62% to -$21.1 million in 2021, then decreased by 8.65% to -$22.9 million in 2022, then dropped by 21.5% to -$27.8 million in 2023, then soared by 62.47% to -$10.4 million in 2024.
- Per Business Quant, the three most recent readings for RAPT's Free Cash Flow are -$10.4 million (Q4 2024), -$17.6 million (Q3 2024), and -$28.2 million (Q2 2024).